Home > News & Media > Calendar > CRDF Commercial Product Delivery Committee Meeting

CRDF Commercial Product Delivery Committee Meeting

CRDF Commercial Product Delivery Committee Meeting

Monday, December 02, 2019, 2:00 PM – 5:00 PM

NOTICE OF A MEETING OF THE CITRUS RESEARCH AND DEVELOPMENT FOUNDATION INC., COMMERCIAL PRODUCT DELIVERY COMMITTEE

Monday December 2, 2019 – 2:00 pm EDT

TIME AND PLACE OF MEETING

A meeting of the Commercial Product Delivery Committee of the Citrus Research and Development Foundation, Inc. will be held on Monday December 2, 2019 at 2:00 p.m. EDT at the Citrus Research and Education Center, Lake Alfred, Florida in Ben Hill Griffin Hall, Room 103. Participants may access the meeting by dialing 1-800-567-5900 and entering participant access code 393338#.

Below are a few phone tips to be mindful of when on a conference call. To minimize interruptions or distractions, please follow these guidelines:

• When speaking, please say your name so that the minutes can be properly captured.
• Please mute your line whenever you are not speaking (mute button on phone or *6) to prevent background noise from disrupting the meeting and ensuring the best sound quality during the call.
• Refrain from using headsets, speakers, cordless phones, etc., as they can create static or echo on your conference calls.
• If you have any problems during your call, please text Deidra Whatley at 863-412-1071, or Audrey Nowicki at 412-554-5143. We will try to resolve the problem immediately.

Pursuant to the provisions of the Americans with Disabilities Act, any person requiring special accommodations to participate in this meeting is asked to advise the Foundation at least 72 hours before the meeting by contacting Deidra Whatley by phone at 863-956-8817 (office) or 863-412-1071 (cell) or by email at d.whatley@citrusrdf.org or Audrey Nowicki by phone at (863) 956-5894 or by email at anowicki@citrusrdf.org

AGENDA
A. Call to Order
B. Roll Call/Determination of Quorum
C. Approval of Minutes of October 16, 2019 CPDC Meeting*
D. Discussion – Continuation Funding of Transformation Labs*
E. Update on Bayer Joint Steering Committee Meeting
F. Discussion of Trunk Injection Modality
G. Other Business
H. Adjournment